Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Atara Biotherapeutics stock in Canada | $13.56
Own Atara Biotherapeutics shares in just a few minutes.
Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics stocks (ATRA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14 – an increase of 2.49% over the previous week. Atara Biotherapeutics employs 480 staff and has a trailing 12-month revenue of around $3.6 million.
How to buy Atara Biotherapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ATRA in this case.
- Research Atara Biotherapeutics stocks. The platform should provide the latest information available.
- Buy your Atara Biotherapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Atara Biotherapeutics?
- Has coronavirus impacted Atara Biotherapeutics shares?
- Atara Biotherapeutics shares summary
- Compare share dealing platforms
- Is Atara Biotherapeutics stock a buy or sell?
- Atara Biotherapeutics performance over time
- Can I short Atara Biotherapeutics shares?
- Atara Biotherapeutics's financials
- How volatile are Atara Biotherapeutics shares?
- Does Atara Biotherapeutics pay a dividend?
- Other common questions
How has Coronavirus impacted Atara Biotherapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Atara Biotherapeutics's stock price has had significant positive movement.
Its last market close was $13.56, which is 2.73% up on its pre-crash value of $13.19 and 200.00% up on the lowest point reached during the March crash when the stocks fell as low as $4.52.
If you had bought $1,000 worth of Atara Biotherapeutics stocks at the start of February 2020, those stocks would have been worth $572.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $983.37.
Atara Biotherapeutics stock priceUse our graph to track the performance of ATRA stocks over time.
Atara Biotherapeutics stocks at a glance
|Latest market close||$13.56|
|52-week range||$11.33 - $26.1|
|50-day moving average||$14.425|
|200-day moving average||$15.464|
|Wall St. target price||$35.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.071|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Atara Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Atara Biotherapeutics price performance over time
|1 month (2021-07-02)||-14.82%|
|3 months (2021-04-30)||-3.56%|
Atara Biotherapeutics financials
|Revenue TTM||USD$3.6 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-47.13%|
|Return on equity TTM||-95.56%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
How to short and sell Atara Biotherapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "ATRA.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 12.1 million Atara Biotherapeutics stocks held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 3.7% up from 11.7 million last month.
There are a few different ways that this level of interest in shorting Atara Biotherapeutics stocks can be evaluated.
Atara Biotherapeutics's "short interest ratio" (SIR)
Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics stocks currently shorted divided by the average quantity of Atara Biotherapeutics stocks traded daily (recently around 916927.23823976). Atara Biotherapeutics's SIR currently stands at 13.18. In other words for every 100,000 Atara Biotherapeutics stocks traded daily on the market, roughly 13180 stocks are currently held short.
However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics stocks, or, against the total number of tradable Atara Biotherapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.14% of the outstanding stocks (for every 100,000 Atara Biotherapeutics stocks in existence, roughly 140 stocks are currently held short) or 0.1979% of the tradable stocks (for every 100,000 tradable Atara Biotherapeutics stocks, roughly 198 stocks are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Atara Biotherapeutics.
Find out more about how you can short Atara Biotherapeutics stock.
Atara Biotherapeutics stock dividends
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Atara Biotherapeutics stock price volatility
Over the last 12 months, Atara Biotherapeutics's stocks have ranged in value from as little as $11.33 up to $26.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.4363. This would suggest that Atara Biotherapeutics's stocks are significantly more volatile than the average for this exchange and represent a higher risk.
Atara Biotherapeutics overview
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Stocks similar to Atara Biotherapeutics
Atara Biotherapeutics in the news
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Trellus Management Company, LLC Buys Vertex Energy Inc, Genius Sports, Coupang Inc, Sells dMY Technology Group Inc II, MercadoLibre Inc, Amazon.com Inc
Short Report: Fisker short interest hits three-week high of 25%
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.